Table 2 |
||||||||||||||||||
|
Characteristics of patients included in the LE skin biopsies: cumulative ACR criteria, autoantibody specificities, and medication |
||||||||||||||||||
|
Patient characteristics |
||||||||||||||||||
|
|
||||||||||||||||||
|
SBC/co-loc |
No. |
Gender |
Age |
A |
C |
R |
Prednisone |
Hydroxychloroquine |
Azathioprine |
Autoantibody |
||||||||
|
(Years) |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
(mg/day) |
(mg/day) |
(mg/day) |
specificities |
|||
|
|
||||||||||||||||||
|
+/+ |
1 |
F |
45 |
- |
- |
- |
- |
- |
+ |
+ |
- |
- |
+ |
+ |
- |
75 |
SSA/SSB/dsDNA |
|
|
+/+ |
2 |
F |
51 |
+ |
- |
+ |
- |
- |
+ |
- |
- |
+ |
- |
+ |
5 |
- |
100 |
SSA/SSB |
|
+/+ |
3 |
F |
70 |
- |
+ |
- |
- |
- |
- |
- |
- |
+ |
+ |
+ |
10 |
200 |
25 |
Sm/SSA/nRNP |
|
-/- |
4 |
M |
47 |
- |
+ |
+ |
- |
- |
- |
- |
- |
+ |
+ |
- |
- |
- |
SSA/SSB |
|
|
-/- |
5 |
F |
45 |
+ |
+ |
- |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
- |
5 |
- |
Sm/nRNP/CL |
|
+/- |
6 |
F |
50 |
+ |
+ |
- |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
12.5 |
600 |
- |
Sm/nRNP/CL |
|
+/+ |
7 |
F |
49 |
+ |
+ |
- |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
10 |
600 |
- |
Sm/nRNP/CL |
|
+/- |
8 |
F |
39 |
+ |
- |
+ |
+ |
+ |
- |
- |
- |
- |
+ |
+ |
60 |
- |
- |
dsDNA |
|
+/+ |
9 |
F |
41 |
+ |
- |
- |
- |
+ |
+ |
- |
- |
- |
+ |
+ |
2.5 |
- |
75 |
SSA/SSB/dsDNA |
|
+/+ |
10 |
F |
45 |
- |
+ |
- |
- |
+ |
+ |
+ |
- |
+ |
+ |
+ |
5 |
400 |
- |
dsDNA |
|
+/+ |
11 |
F |
46 |
- |
+ |
- |
- |
+ |
+ |
+ |
- |
+ |
+ |
+ |
5 |
400 |
- |
dsDNA |
|
+/- |
12 |
F |
38 |
- |
+ |
- |
- |
+ |
- |
- |
- |
- |
+ |
+ |
- |
- |
- |
dsDNA |
|
-/- |
13 |
F |
75 |
- |
- |
- |
- |
+ |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
dsDNA/CL |
|
+/- |
14 |
F |
33 |
+ |
- |
- |
- |
+ |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
SSA/Sm/nRNP/dsDNA |
|
+/+ |
15 |
F |
58 |
- |
+ |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
SSA/dsDNA |
|
+/- |
16 |
F |
38 |
- |
+ |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
SSA/dsDNA |
|
-/- |
17 |
F |
49 |
- |
+ |
+ |
- |
- |
- |
+ |
- |
+ |
- |
+ |
- |
800 |
- |
dsDNA/CL |
|
+/+ |
18 |
F |
49 |
- |
+ |
- |
+ |
+ |
+ |
- |
- |
+ |
+ |
+ |
7.5 |
- |
- |
dsDNA |
|
+/+ |
19 |
M |
35 |
- |
+ |
+ |
- |
- |
- |
- |
- |
+ |
+ |
- |
- |
- |
SSA/dsDNA |
|
|
+/- |
20 |
F |
26 |
+ |
- |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
nRNP/Sm/dsDNA |
|
|
||||||||||||||||||
|
ACR criteria numbered according to Bombardier et al. [19]: 1, malar (or 'butterfly') rash; 2, discoid rash; 3, sensitivity to light, or photosensitivity; 4, oral ulcers; 5, arthritis; 6, serositis; 7, kidney disorder; 8, neurologic disorder; 9, blood abnormalities; 10, positive antiphospholipid antibody test; 11, immunologic disorder, including lupus anticoagulant, positive anti-double-stranded DNA, false-positive syphilis test, or positive anti-Smith test (such as anticardiolipin). + and - indicate cumulative presence or absence, respectively, of a particular criterion. In the leftmost column, +/- indicates biopsies containing SBCs but no apparent co-localisation, +/+ indicates biopsies containing co-localisation of inflammatory lesions and SBCs, and - indicates biopsies without SBCs. ACR, American College of Rheumatology; co-loc, co-localisation; F, female, LE, lupus erythematosus; M, male; SBC, sunburn cell; UVB, ultraviolet B light. |
||||||||||||||||||
|
Reefman et al. Arthritis Research & Therapy 2006 8:R156 doi:10.1186/ar2051 |
||||||||||||||||||
